Pathology in Germany: Prostate Cancer

  • November 2010
  • -
  • Global Data

The report is an essential source of information and analysis on the German prostate cancer therapeutics industry . The report provides comprehensive data on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the major industry developments shaping and driving the German prostate cancer therapeutics industry, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. The report provides valuable insights into the new product development within the global prostate cancer segment . It quantifies the unmet need in the German prostate cancer therapeutics industry, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Research Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized German prostate cancer therapeutics industry revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, projection for 11 years to 2020.
- Insightful review of the key market drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales projections .
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales projection .
- Analysis of unmet need in the industry and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, industry ing rights and launch analysis.
- Analysis of the current and future industry competition in the German Prostate Cancer therapeutics industry . Firms profiles including business description, financial overview and SWOT analysis. Key future industry players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics industry . Merger and Acquisition (M&A analysis) which includes Merger and Acquisition deals by size and geography.
- Strategic assessment of the industry through industry impact analysis, future industry scenario and industry player analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics industry in Germany.

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior industry quantification analysis by
- Understanding the trends shaping and driving the German prostate cancer therapeutics industry .
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing industry sizing projections and quantified growth opportunities in the German prostate cancer therapeutics industry up to 2020.
- Quantifying the patient population in the German to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and industry ing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently industry ed products.
- Identifying industry entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the industry by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the German prostate cancer therapeutics industry from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the German prostate cancer therapeutics industry landscape? Identify, understand and decide.

Table Of Contents

1 Table of contents 4
I. 1 List of Data tables 7
I. 2 List of Charts 8
2 Disease Data 10
II. 1 Overview 10
II. 1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10
II. 1.2 Jewett-Whitmore system 11
II. 2 Epidemiology 12
II. 3 Etiology 12
II. 4 Symptoms 12
II. 4.1 Localized or Locally Advanced Prostate Cancer 12
II. 4.2 Metastatic Prostate Cancer 13
II. 5 Diagnosis 13
II. 5.1 Digital Rectal Examination 13
II. 5.2 Prostate Specific Antigen Test 13
II. 5.3 Transrectal Ultrasound 14
II. 5.4 Prostate Biopsy 14
II. 6 Pathology 15
II. 6.1 Grading 15
II. 7 Treatment 15
II. 7.1 Watchful Waiting 15
II. 7.2 Radiation therapy 15
II. 7.3 Surgery 16
II. 7.4 Hormone therapy 17
II. 7.5 Chemotherapy Options 18
II. 7.6 Other Treatments Being Studied 19
II. 8 Treatment Guidelines 19

III March ket Characterization 20
III. 1 Germany 20
III. 1.1 March ket Size 20
III. 1.2 Drivers and Barriers 26
III. 1.3 Impact on the March ket 28
III. 1.4 Forecasted data s 29
III. 1.5 Drug Sales 35
III. 1.6 Pricing and Reimbursements 39

IV Competitor Assessment 40
IV. 1 Strategic Competitor Assessment 40
IV. 1.1 Overview 40
IV. 1.2 Benchmarking 40
IV. 1.3 Current Competitor Assessment 44
IV. 2 Launch Analysis and Sales Forecasted data s 45
IV. 3 Product Profiles 46
IV. 3.1 Taxotere (docetaxel) 47
IV. 3.2 Casodex (Bicalutamide) 50
IV. 3.3 Zoladex (Goserelin) 55
IV. 3.4 Eligard (leuprolide acetate) 57
IV. 3.5 Firmagon (degarelix) 62
IV. 3.6 November antrone (Mitoxantrone hydrochloride) 64
IV. 3.7 Emcyt (estramustine) 66
IV. 3.8 Trelstar (triptorelin) 68
IV. 3.9 Eulexin 69
IV. 3.10 Delestrogen 71
IV. 3.11 Gynodiol 72
IV. 3.12 Estrace tablet 73
IV. 3.13 Tace 73
IV. 3.14 Nilandrone 74
IV. 3.15 Premarin 75
IV. 3.16 Sales Forecasted data for Trelstar, December apeptyl, Gonapeptyl, Flutamide, Estradiol 76

V Pipeline Assessment 77
V. 1 Overview 77
V. 2 Pipeline Analysis by Phase of Development 78
V. 3 Pipeline by Mechanism of Action 79
V. 4 Strategic Pipeline Assessment 80
V. 4.1 Technology Trends Analytical Framework 80
V. 5 Trends in Prostate Cancer Pipeline 81
V. 5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying November el Targets for Prostate Cancer Drugs 81
V. 5.2 Molecules with November el Mechanism of Action Strengthening Prostate Cancer Pipeline 81
V. 5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 81
V. 6 Partners in Research and Development 82
V. 6.1 Licensing Agreements by Phase of Development 82
V. 6.2 Licensing Agreements by Geography 85
V. 6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 85
V. 7 Most Promising Drugs’ Profiles 86
V. 7.1 Provenge (sipuleucel-T) 87
V. 7.2 Jevtana (cabazitaxel) 90
V. 7.3 Aflibercept (VEGF Trap) 91
V. 7.4 Ipilimumab 94
V. 7.5 Abiraterone Acetate (CB7630) 96
V. 7.6 Zibotentan (ZD4054) 98
V. 7.7 Sprycel (dasatinib) 100
V. 7.8 MDV3100 102
V. 8 Prostate Cancer Pipeline - Pre-clinical Phase 105
V. 9 Prostate Cancer Pipeline - Phase I 106
V. 10 Prostate Cancer Pipeline - Phase II 108
V. 11 Prostate Cancer Pipeline - Phase III 115
V. 12 Key Takeaway 116

VI Unmet Need and Target Product Profile 117
VI. 1 Unmet Need 119
VI. 1.1 Hormone-independent Metastatic Prostate Cancer Therapy 119
VI. 1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 120
VI. 2 Opportunity for Target Product 121
VI. 3 Target Product Profile 123
VI. 3.1 Ideal Characteristics 123
VI. 3.2 Target Product Description 124
VI. 4 Key Takeaway 124

VII Strategic Assessment 125
VII. 1 Key Events Impacting the Future March ket 125
VII. 2 March ket Impact Analysis 126
VII. 3 Future March ket Scenario 126
VII. 4 Firms Analysis 127
VII. 4.1 March ket Leadership 127
VII. 4.2 Future Players in the March ket 128
VII. 5 Key Takeaway 128

VIII Company Profiles 129
VIII. 1 Sanofi-aventis 129
VIII. 1.1 Business Overview 129
VIII. 1.2 Financial Overview 131
VIII. 1.3 SWOT 131
VIII. 1.4 Oncology Focus 136
VIII. 2 Pfizer Inc. 136
VIII. 2.1 Business Overview 136
VIII. 2.2 Financial Overview 137
VIII. 2.3 SWOT 138
VIII. 2.4 Oncology Focus 144
VIII. 3 AstraZeneca 145
VIII. 3.1 Business Overview 145
VIII. 3.2 Financial Overview 147
VIII. 3.3 SWOT 147
VIII. 3.4 Oncology Focus 151
VIII. 4 Bristol-Myers Squibb 152
VIII. 4.1 Business Overview 152
VIII. 4.2 Financial Overview 153
VIII. 4.3 SWOT 154
VIII. 4.4 Oncology Focus 159
VIII. 5 Medivation 160
VIII. 5.1 Business Overview 160
VIII. 5.2 SWOT 161
VIII. 5.3 Oncology Focus 164
VIII. 6 Takeda Pharmaceuticals 164
VIII. 6.1 Business Overview 164
VIII. 6.2 SWOT 165
VIII. 7 Dendreon Corporation 166
VIII. 7.1 Business Overview 166
VIII. 7.2 SWOT 167
VIII. 8 Johnson and Johnson 170
VIII. 8.1 Business Overview 170
VIII. 8.2 SWOT 171
VIII. 8.3 Oncology Focus 178
VIII. 9 Auron Healthcare GmbH 179
VIII. 9.1 Business Overview 179
VIII. 10 Oncogenex Pharmaceuticals, Inc. 179
VIII. 10.1 Business Overview 179
VIII. 11 Agennix AG 179
VIII. 11.1 Business Overview 179
VIII. 12 GTx, Inc. 180
VIII. 12.1 Business Overview 180
VIII. 13 GlaxoSmithKline plc. 180
VIII. 13.1 Business Overview 180
VIII. 13.2 Financial Overview 181
VIII. 13.3 SWOT 181
VIII. 13.4 Oncology Focus 187

IX MandA Analysis 189
IX. 1 Key Highlights 189
IX. 2 Key Deals’ Analysis 190
IX. 2.1 Johnson and Johnson Takes Over Cougar Biotechnology 190
IX. 2.2 Endo Pharmaceuticals Takes Over Indevus Pharmaceuticals 190
IX. 2.3 Tolmar Holding Takes Over QLT USA from QLT 191
IX. 2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 191
IX. 2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly and Co. 191
IX. 2.6 Quest PharmaTech Takes Over Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 191
IX. 2.7 VaxOnco Takes Over Rights to Onyvax-P Cell Vaccine From Onyvax 191
IX. 2.8 GPC Biotech Merges with Agennix 191
IX. 2.9 Eli Lilly Takes Over ImClone 192
IX. 2.10 BBM Holdings Takes Over YM BioSciences 192
IX. 2.11 Sagent Pharmaceuticals Takes Over Injectable Generic Drug Applications of Spectrum Pharmaceuticals 192
IX. 3 Merger and Acquisition Deals by Geography 193
IX. 4 Merger and Acquisition Deals by Deal Size 193

X Expert Opinion 194
X. 1 Germany 194

XI Appendix 195
XI. 1 March ket Definitions 195
XI. 2 Abbreviations 195
XI. 3 Research Methodology 197
XI. 3.1 Coverage 197
XI. 3.2 Secondary Research 198
XI. 3.3 Forecasted data ing 198
XI. 3.4 Primary Research 201
XI. 3.5 Expert Panel validation 201
XI. 3.6 Contact Us 201
XI. 3.7 Disclaimer 201
XI. 3.8 Sources 202
1.1 List of Data tables
Data table 1: Prostate Cancer Therapeutics March ket, Global, Staging of the Prostate Cancer, 2010 11
Data table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Data table 3: Prostate Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2001 to 2009 20
Data table 4: Prostate Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2001 to 2009 22
Data table 5: Prostate Cancer Therapeutics March ket, Germany, Patient Volume (’000s), from 2001 to 2009 23
Data table 6: Prostate Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2001 to 2009 24
Data table 7: Prostate Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2009 to 2020 29
Data table 8: Prostate Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2009 to 2020 30
Data table 9: Prostate Cancer Therapeutics March ket, Germany, Patient Volume (’000s), from 2009 to 2020 31
Data table 10: Prostate Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2009 to 2020 32
Data table 11: Prostate Cancer Therapeutics March ket, Germany, Hormone-refractory Prostate Cancer Drug Sales (USD Million), from 2001 to 2010 36
Data table 12: Prostate Cancer Therapeutics March ket, Germany, Hormone-refractory Prostate Cancer Drug Sales (USD Million), from 2011 to 2020 36
Data table 13: Prostate Cancer Therapeutics March ket, Germany, Hormone-dependent Prostate Cancer Drug Sales (USD Million), from 2001 to 2010 38
Data table 14: Prostate Cancer, Germany, Hormone-dependent Prostate Cancer Drug Sales (USD Million), from 2011 to 2020 38
Data table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 41
Data table 16: Prostate Cancer, Global, Chemotherapy, Safety Company Profile: Standard Care Treatment, 2010 42
Data table 17: Prostate Cancer, Global, Hormone Therapy, Safety Company Profile: Standard Care Treatment, 2010 43
Data table 18: Prostate Cancer, Germany, Benchmarking Major March keted Products, 2010 46
Data table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 51
Data table 20: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 58
Data table 21: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 59
Data table 22: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 60
Data table 23: Prostate Cancer, Global, Licensing Agreements, from 2009 to 2010 84
Data table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 86
Data table 25: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 86
Data table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, 2010 105
Data table 27: Prostate Cancer, Global, Phase I Pipeline, 2010 106
Data table 28: Prostate Cancer, Global, Phase II Pipeline, 2010 108
Data table 29: Prostate Cancer, Global, Phase III Pipeline, 2010 115
Data table 30: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the March ket, 2010 123
Data table 31: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the March ket, 2010 124
Data table 32: Prostate Cancer, Johnson and Johnson, Oncology Late Stage Pipeline by Indication, 2010 178
Data table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 179
Data table 34: Prostate Cancer, Global, Merger and Acquisition Deals by Geography, 2010 189
1.2 List of Charts
Chart 1: Prostate Cancer Therapeutics March ket, Global, Treatment Guidelines, 2010 19
Chart 2: Prostate Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2001 to 2009 20
Chart 3: Prostate Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2001 to 2009 21
Chart 4: Prostate Cancer Therapeutics March ket, Germany, Patient Volume (’000s), from 2001 to 2009 23
Chart 5: Prostate Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2001 to 2009 24
Chart 6: Prostate Cancer Therapeutics March ket, Germany, March ket Drivers and Restraints, 2009 26
Chart 7: Prostate Cancer Therapeutics March ket, Germany, Historical data al Events Impact on the March ket, 2010 28
Chart 8: Prostate Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2009 to 2020 29
Chart 9: Prostate Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2009 to 2020 30
Chart 10: Prostate Cancer Therapeutics March ket, Germany, Patient Volume (’000s), from 2009 to 2020 31
Chart 11: Prostate Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2009 to 2020 32
Chart 12: Prostate Cancer Therapeutics March ket, Germany, Future March ket Drivers and Restraints, from 2009 to 2020 34
Chart 13: Prostate Cancer Therapeutics March ket, Germany, Hormone-refractory Prostate Cancer Drug Sales (USD Million), from 2001 to 2020 35
Chart 14: Prostate Cancer Therapeutics March ket, Germany, Hormone-dependent Prostate Cancer Drug Sales (USD Million), from 2001 to 2020 37
Chart 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, Chemotherapy Drugs, 2010 44
Chart 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, Hormone Therapy Drugs, 2010 45
Chart 17: Prostate Cancer Therapeutics March ket, Germany, Sales Forecasted data by Therapies, from 2001 to 2020 46
Chart 18: Prostate Cancer, Global, Taxotere, Chemical Structure 48
Chart 19: Prostate Cancer, Global, Taxotere, LCM Activities, from 2004 to 2010 49
Chart 20: Prostate Cancer, Germany, Taxotere, Sales (USD Million), from 2004 to 2020 50
Chart 21: Prostate Cancer, Global, Casodex, Chemical Structure 51
Chart 22: Prostate Cancer, Global, Casodex, LCM Activities, from 2004 to 2010 54
Chart 23: Prostate Cancer, Germany, Casodex, Sales (USD Million), from 2001 to 2020 55
Chart 24: Prostate Cancer, Global, Zoladex, Chemical Structure 56
Chart 25: Prostate Cancer, Germany, Zoladex, Sales Forecasted data (USD Million), from 2001 to 2020 57
Chart 26: Prostate Cancer, Global, Eligard, Chemical Structure 58
Chart 27: Prostate Cancer, Germany, Leuprolide (Eligard), Sales Forecasted data (USD Million), from 2001 to 2020 61
Chart 28: Prostate Cancer, Global, Firmagon, Chemical Structure 62
Chart 29: Prostate Cancer, Germany, Firmagon, Sales Forecasted data (USD Million), from 2008 to 2020 64
Chart 30: Prostate Cancer, Global, November atrone, Chemical Structure 64
Chart 31: Prostate Cancer, Germany, Mitoxantrone, Sales Forecasted data (USD Million), from 2001 to 2020 66
Chart 32: Prostate Cancer, Global, Emcyt, Chemical Structure 67
Chart 33: Prostate Cancer, Germany, Estramustine, Sales Forecasted data (USD Million), from 2001 to 2020 67
Chart 34: Prostate Cancer, Global, Trelstar, Chemical Structure 68
Chart 35: Prostate Cancer, Global, Eulexin, Chemical Structure 69
Chart 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 71
Chart 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 72
Chart 38: Prostate Cancer, Global, Estrace, Chemical Structure 73
Chart 39: Prostate Cancer, Global, Tace, Chemical Structure 74
Chart 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 74
Chart 41: Prostate Cancer, Global, Premarin, Chemical Structure 75
Chart 42: Prostate Cancer, Germany, Combined sales of Trelstar, December apeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecasted data (USD Million), from 2001 to 2020 76
Chart 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 77
Chart 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 78
Chart 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 79
Chart 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 80
Chart 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 81
Chart 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, from 2009 to 2010 82
Chart 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 85
Chart 50: Prostate Cancer, Germany, Provenge, Sales Forecasted data (USD Million), from 2009 to 2020 89
Chart 51: Prostate Cancer, Germany, Jevtana, Sales Forecasted data (USD Million), from 2001 to 2020 91
Chart 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 92
Chart 53: Prostate Cancer, Germany, Aflibercept, Sales Forecasted data (USD Million), from 2009 to 2020 93
Chart 54: Prostate Cancer, Germany, Ipilimumab, Sales Forecasted data (USD Million), from 2009 to 2020 95
Chart 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 96
Chart 56: Prostate Cancer, Germany, Abiraterone, Sales Forecasted data (USD Million), from 2009 to 2020 98
Chart 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 99
Chart 58: Prostate Cancer, Germany, Zibotentan, Sales Forecasted data (USD Million), from 2009 to 2020 100
Chart 59: Prostate Cancer, Germany, Sprycel, Sales Forecasted data (USD Million), from 2009 to 2020 102
Chart 60: Prostate Cancer, Global, MDV3100, Chemical Structure 103
Chart 61: Prostate Cancer, Germany, MDV3100, Sales Forecasted data (USD Million), from 2009 to 2020 104
Chart 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 117
Chart 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 118
Chart 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 118
Chart 65: Prostate Cancer, Germany, Prostate Cancer, Opportunity and Unmet Need, 2010 119
Chart 66: Prostate Cancer, Germany, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 122
Chart 67: Prostate Cancer, Germany, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 123
Chart 68: Prostate Cancer, Global, Key Events Impacting the Future March ket 125
Chart 69: Prostate Cancer, Germany, Implications for Future March ket Competition, 2010 126
Chart 70: Prostate Cancer, Global, Future Players in the March ket, 2010 128
Chart 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 129
Chart 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 130
Chart 73: Prostate Cancer, Global, Sanofi-aventis, SWOT, 2010 131
Chart 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 136
Chart 75: Prostate Cancer, Global, Pfizer, SWOT 2010 138
Chart 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 144
Chart 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 145
Chart 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 146
Chart 79: Prostate Cancer, Global, AstraZeneca, SWOT 2010 147
Chart 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 151
Chart 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 151
Chart 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 152
Chart 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 153
Chart 84: Prostate Cancer, Global, Firms Bristol-Myers Squibb, SWOT, 2010 154
Chart 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 159
Chart 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 160
Chart 87: Prostate Cancer, Global, Medivation, SWOT 2010 161
Chart 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT 2010 165
Chart 89: Prostate Cancer, Global, Dendreon Corporation, SWOT 2010 167
Chart 90: Prostate Cancer, Global, Johnson and Johnson, SWOT 2010 172
Chart 91: Prostate Cancer, Johnson and Johnson, Late Stage Pipeline by Therapy Area, 2010 178
Chart 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT 2010 181
Chart 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 187
Chart 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 188
Chart 95: Prostate Cancer, Global, Merger and Acquisition Deals by Geography of Target Firms, 2010 193
Chart 96: Prostate Cancer, Global, Merger and Acquisition Deals by Deal Size, 2010 193
Chart 97: Prostate Cancer, Germany, Key Data Inputs from KOL Interviews, 2010 194
Chart 98: GlobalData March ket Forecasted data ing Model 200

Companies mentioned

Sanofi-aventis
Pfizer Inc.
AstraZeneca
Bristol-Myers Squibb
Medivation
Takeda Pharmaceuticals
Dendreon Corporation
Johnson and Johnson
Auron Healthcare GmbH
Oncogenex Pharmaceuticals, Inc.
Agennix AG
GTx, Inc.
GlaxoSmithKline plc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.